Core Viewpoint - The company is changing its accounting firm from Tianjian to Grant Thornton to enhance audit independence and objectivity, following regulatory requirements and after thorough communication with the previous firm [1][5][6]. Group 1: Accounting Firm Change - The new accounting firm to be appointed is Grant Thornton [1]. - The previous accounting firm was Tianjian, which has provided audit services for nine consecutive years [5]. - The change is aimed at improving the company's operational standards and ensuring a more scientific and efficient audit process [5][6]. Group 2: Grant Thornton's Profile - Grant Thornton was established in 1981 and has nearly 6,000 employees, including 1,359 certified public accountants [1][2]. - The firm has a history of providing audit services to 297 listed companies in 2024, with a total audit revenue of 210,326.95 million yuan [2]. - Grant Thornton has not faced any criminal penalties in the last three years and has a professional liability insurance coverage of 900 million yuan [2][4]. Group 3: Communication and Approval Process - The company has communicated with Tianjian regarding the change, and Tianjian has no objections [5][6]. - The board of directors approved the change with a unanimous vote of 7 in favor [6]. - The change will take effect upon approval by the shareholders' meeting [6].

浙江金道科技股份有限公司（以下简称"公司"）于 2025 年 7 月 5 日召开 第三届董事会第五次会议、第三届监事会第五次会议，会议审议通过《关于续聘 会计师事务所的议案》，同意继续聘请天健会计师事务(特殊普通合伙)为公司 一、拟续聘会计师事务所事项的情况说明 天健会计师事务所（特殊普通合伙）（以下简称"天健"）具有从事证券、 期货相关业务资格，具备为上市公司提供审计服务的经验与能力，在为公司提供 审计服务的工作中，能够遵循独立、客观、公正的职业准则，恪尽职守，为公司 提供了高质量的审计服务，其出具的报告能够客观、真实地反映公司的实际情况、 财务状况和经营成果，切实履行了审计机构职责，从专业角度维护了公司及股东 的合法权益。因此，公司拟继续聘请天健会计师事务所（特殊普通合伙）担任公 司 2025 年度财务审计机构。公司董事会提请股东大会授权公司管理层根据年度 审计工作量与审计机构协商确定 2025 年度审计费用。 二、拟续聘会计师事务所的基本信息 证券代码：301279 证券简称：金道科技 公告编号：2025-038 浙江金道科技股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 ...

Group 1 - The core point of the announcement is that Zhejiang Shengda Bio-Pharm Co., Ltd. is issuing A-shares to specific investors, with a total of 17,840,666 shares at a price of 15 yuan per share, raising a total of approximately 267.61 million yuan [1][16][18] - The shares will be listed on the Shanghai Stock Exchange after a lock-up period of six months following the issuance [1][21] - The company is a leading supplier of biotin and folic acid, focusing on the research, production, and sales of vitamins, biological preservatives, food additives, and feed additives [9][18] Group 2 - The issuance process included several board meetings and approvals from the shareholders, with the final approval from the China Securities Regulatory Commission (CSRC) received on January 24, 2025 [10][11][19] - The issuance is targeted at specific institutional investors, including private equity funds and asset management companies, ensuring compliance with regulatory requirements [12][31] - The funds raised will be deposited into a dedicated account, and the company has established a three-party supervision agreement to ensure the proper use of the funds [20][21]

Core Viewpoint - Chongqing Zhenbao Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, with CITIC Securities as the sponsor [2]. Company Overview - Zhenbao Technology focuses on providing manufacturing equipment vacuum chamber components and surface treatment solutions for the integrated circuit and display panel industries [2]. - The main products include silicon, quartz, silicon carbide, and alumina ceramic components, as well as surface treatment services such as thermal spraying regeneration, anodizing, and precision cleaning [2]. Financial Performance - Projected revenues for Zhenbao Technology from 2022 to 2024 are 386 million yuan, 506 million yuan, and 635 million yuan respectively [2]. - Projected net profits for the same period are 81.62 million yuan, 108 million yuan, and 152 million yuan respectively [2]. Key Financial Metrics - Total assets are projected to reach 1.268 billion yuan in 2024, up from 1.021 billion yuan in 2023 and 552.33 million yuan in 2022 [3]. - The company's net profit is expected to increase to 151.91 million yuan in 2024 from 107.81 million yuan in 2023 and 81.62 million yuan in 2022 [3]. - The return on equity is projected to be 17.10% in 2024, down from 24.46% in 2023 and 28.92% in 2022 [3]. Ownership Structure - The actual controller, Wang Bing, directly holds 51.625 million shares, accounting for 44.33% of the total share capital, and controls an additional 12.88% through partnerships [3]. - Wang Bing's family members, including his spouse and siblings, are also significant shareholders and act in concert with him [4].

Core Viewpoint - The company intends to reappoint Tianjian Accounting Firm as its auditor, highlighting the firm's qualifications and experience in the industry [1][6]. Group 1: Basic Information of the Accounting Firm - Tianjian Accounting Firm, established in December 1983 and restructured in July 2011, is one of the earliest firms authorized to provide securities services in China [1]. - As of December 31, 2024, Tianjian has 241 partners and 2,356 registered accountants, with 904 having signed securities service audit reports [1]. Group 2: Financial Performance - In 2024, Tianjian's total revenue was 2.969 billion yuan, with audit service revenue at 2.563 billion yuan and securities and futures business revenue at 1.465 billion yuan [2]. - The firm audited 756 listed companies for their 2024 annual reports, with total audit fees amounting to 735 million yuan [2]. Group 3: Client Base and Risk Management - Tianjian's clients are primarily from various sectors, including manufacturing, information technology, retail, and utilities, among others [2]. - The firm has established a professional risk fund and purchased professional liability insurance, with cumulative compensation limits exceeding 200 million yuan as of the end of 2024 [2]. Group 4: Legal and Regulatory Compliance - In the past three years, Tianjian faced four administrative penalties and 13 supervisory measures, but no criminal penalties [3]. - The project partners and auditors have not faced criminal penalties and have maintained compliance with ethical standards [5]. Group 5: Audit Project Details - The project partner, Ye Xicheng, has been involved in auditing since 2003 and has signed reports for several public companies [3][4]. - The expected audit fees for the 2025 annual report and internal control audit are 2.18 million yuan, with 1.65 million yuan for the annual report audit and 530,000 yuan for internal control audit [5]. Group 6: Approval Process - The audit committee approved the reappointment of Tianjian on June 19, 2025, and the board of directors unanimously supported the decision [6]. - The reappointment is subject to approval by the company's shareholders and will take effect upon their approval [6].

Core Viewpoint - The company has decided to reappoint Tianjian Accounting Firm (Special General Partnership) as its auditor for the fiscal year 2025, following approval from the board and supervisory committee, and will present this decision to the shareholders for final approval [1][6][7] Group 1: Auditor Information - Tianjian Accounting Firm was established on July 18, 2011, and is located in Hangzhou, Zhejiang Province [1] - The firm has 241 partners and 2,356 registered accountants, with 904 of them having signed audit reports for securities services [1] - The total revenue of the firm is 2.969 billion yuan, with audit revenue accounting for 2.563 billion yuan and securities business revenue at 1.465 billion yuan [1] Group 2: Audit History and Compliance - The firm has faced civil lawsuits related to its auditing practices in the past three years but has fulfilled its legal obligations and does not expect these to negatively impact its performance [4] - Tianjian Accounting Firm has received four administrative penalties, 13 supervisory measures, and eight self-regulatory measures in the last three years, but has not faced criminal penalties [4][5] - The firm has a cumulative risk fund and professional insurance exceeding 200 million yuan, complying with relevant regulations [1] Group 3: Project Team Information - The project partner and signing accountant for the audit is Lin Wang, who has been a registered accountant since 2009 and has experience in auditing listed companies [2][5] - The signing accountant Li Weijie has been with the firm since 2011 and has provided audit services to the company since 2022 [2][5] - The quality review personnel, Wei Biaowen, has been a registered accountant since 2003 and has signed or reviewed 13 audit reports for listed companies in the past three years [2][5] Group 4: Approval Process - The company has conducted a thorough review of the auditor's independence, professional competence, and integrity, concluding that Tianjian Accounting Firm meets the qualifications to provide auditing services [6] - The board has agreed to submit the proposal for reappointment to the shareholders for approval, with the audit fees to be determined based on market principles [6][7]

证券简称：圣达生物 证券代码：603079 浙江圣达生物药业股份有限公司 向特定对象发行A股股票 发行情况报告书 保荐人（主承销商） 二〇二五年六月 浙江圣达生物药业股份有限公司 向特定对象发行 A 股股票发行情况报告书 发行人全体董事、监事及高级管理人员声明 浙江圣达生物药业股份有限公司全体董事、监事及高级管理人员承诺本发行 情况报告书不存在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、 完整性承担相应的法律责任。 公司全体董事签名： 洪 爱 朱勇刚 陈不非 周 斌 徐建新 ZHU JING（朱静） 胡国华 李永泉 陈希琴 公司全体监事签名： 徐 涵 周娟娟 洪灿灿 公司全体非董事高级管理人员签名： ZHU JENNY YI-XUAN 庞 晗 许祥晓 （朱怡萱） 浙江圣达生物药业股份有限公司 年 月 日 浙江圣达生物药业股份有限公 司 向特定对象发行 A 股 票发行情况报告书 目 录 浙江圣达生物药业股份有限公司 向特定对象发行 A 股票发行情况报告书 释 义 在本发行情况报告书中，除非上下文另有所指，下列简称具有如下含义： 圣达生物、发行人、 指 浙江圣达生物药业股份有限公司 公司 本次发行、本次 ...

Group 1 - The report is a verification of the usage of funds raised by Ningbo Huaxiang Electronics Co., Ltd. as of March 31, 2025, prepared by the management [1][3] - The report is intended solely for the issuance of stocks to specific parties and cannot be used for any other purpose [1] - The management is responsible for providing accurate and complete information in accordance with the regulations set by the China Securities Regulatory Commission [2] Group 2 - The total amount raised from the non-public offering was RMB 1,617.55 million, with a net amount of RMB 1,609.69 million after deducting fees [3][4] - As of March 31, 2025, all raised funds have been fully utilized, and the special account for these funds has a balance of RMB 0 [4] - The verification of the fund usage was conducted by Tianjian Accounting Firm, confirming compliance with regulatory guidelines [3][4]

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. is focusing on optimizing governance, enhancing operational efficiency, and maintaining shareholder value amidst a challenging market environment, as evidenced by its financial performance and strategic initiatives [5][10][31]. Meeting Overview - The annual shareholder meeting is scheduled for June 26, 2025, at the company's headquarters in Shanghai [1][3]. - The meeting will include the reading of meeting guidelines, discussion of proposals, and voting by shareholders [4][10]. Financial Performance - In 2024, the company achieved a revenue of 10.938 billion yuan, a decrease of 9.38% year-on-year, while net profit rose to 1.084 billion yuan, an increase of 56.62% [18][21]. - The basic earnings per share increased to 0.8080 yuan, reflecting a growth of 48.72% compared to the previous year [21][31]. - The company reported a total profit of 1.673 billion yuan, up 52.57% year-on-year [22][24]. Operational Efficiency - The company has implemented measures to enhance operational efficiency, resulting in a reduction of total expenses by 28.82% year-on-year [22][23]. - The gross profit margin improved to 39.24%, while the net profit margin increased to 12.18% [26][27]. Strategic Initiatives - The company is focusing on innovation and optimizing its product portfolio, with 31 new research projects initiated and 59 product registrations completed [6][10]. - A significant emphasis is placed on enhancing investor relations and maintaining transparency in financial disclosures, achieving an A-level rating in information disclosure for three consecutive years [8][9]. Future Outlook - The company plans to continue its strategic focus on high-quality development and resource optimization, aiming to enhance its competitive edge in the pharmaceutical industry [10][30]. - The 2025 revenue forecast anticipates a growth of 3.68%, with a focus on cost control and marketing efficiency [29][30].

Core Points - The company is preparing for the 2024 Annual General Meeting (AGM) scheduled for June 25, 2025, to discuss various proposals including financial matters and governance [1][5] - The company plans to apply for a comprehensive credit limit of up to RMB 2.1 billion from banks and financial institutions for operational needs in 2025 [20][21] - The company intends to use up to RMB 300 million of temporarily idle funds for entrusted wealth management, involving related party transactions with China Post Securities [22][24] - The company proposes to authorize the board to handle small-scale rapid financing matters, with a total financing amount not exceeding RMB 300 million [27][30] Meeting Arrangements - The AGM will be held at the company's headquarters in Shanghai, with a combination of on-site and online voting [5][6] - Shareholders must register and present identification documents to participate in the meeting [2][3] - The meeting will include the reading of the meeting rules, election of vote counters, and discussion of various proposals [5][6] Proposals Overview - Proposal 1: Approval of the 2024 Annual Report and its summary [6][7] - Proposal 2: Approval of the Board's work report for 2024 [7] - Proposal 3: Approval of the Supervisory Board's work report for 2024 [8] - Proposal 4: Approval of the Independent Directors' work reports for 2024 [9] - Proposal 5: Confirmation of the directors' remuneration for 2024, with independent directors receiving RMB 100,000 annually [10] - Proposal 6: Confirmation of the supervisors' remuneration for 2024, with specific amounts detailed [10] - Proposal 7: Approval of the 2024 Financial Settlement Report [11] - Proposal 8: Proposal for no cash dividend distribution for 2024 due to lack of profit [12] - Proposal 9: Renewal of the accounting firm for 2025, specifically Tianjian Accounting Firm [12][13] - Proposal 10: Approval of the 2025 Financial Budget Report [18][19] Financial Management - The company aims to enhance fund utilization efficiency and increase returns through entrusted wealth management [24][25] - The company will ensure that the entrusted wealth management does not affect its main business operations [26] - The company plans to maintain a focus on core business areas and increase market development efforts in 2025 [19][20]